English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/164872
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

CTPR390-488 a biotechnological fluorescent nanomolecule that reduces myocardial fibrosis through inhibition of TGFβ signaling

AutorCáceres, Rodrigo; Chavez, Tatiana; Bolado, Patricia; Aires, Antonio; Cortajarena, Aitziber L.; Villar Ramos, Ana V.
Fecha de publicación2017
CitaciónXL SEBBM Congress (2017)
ResumenMyocardial fibroblast activation coupled with extracellular matrix production is a pathological signature of myocardial fibrosis and is governed by the transforming growth factor TGFβ-Smad2/3 signaling. Targeting TGFβ itself to reduce pathological fibrosis carries cellular homeostasis deregulation with adverse consequences. We sought to determine the anti-fibrotic eff ects of 90 kDa heat shock protein (Hsp90) downregulation, a chaperone that associates to the TGFβ cascade in this process. To this end, we utilize a new biotechnological Hsp90 inhibitor CTPR390-488 with specific Hsp90 ligand binding properties that maintain its chaperon activity and a fl uorophore attached to be tracked. Gene and protein detections indicated that CTPR390-488 inhibited collagen synthesis, ultrastructural analysis indicated that collagen deposition was diminished and cell tracking assays showed a decrease in cell motility, similarly to fi broblasts from Hsp90aa1 knock out mouse. The anti-fi brotic effects of CTPR390-488 were associated with TGFβ receptor I–Hsp90 complex disruption through in silico studies and phosphorylation assays indicated inhibition of Smad2/3 activation. Reduction of the extracellular matrix through Hsp90aa1 downregulation or CTPR390-488 action decreased fibroblasts motility and diminished the extent of myocardial fibrosis in the Ang II fibrotic mouse model. An insight into the role of CTPR390-488 as a therapeutic biomarker was proved with plasma measurements indicating increasing concentrations of the biomolecule in the mice subjected to Ang II infusion. In conclusion, this is the first study to demonstrate that a fl uorescent CTPR390-488 blocks collagen expression and motility of myocardial TGFβ-activated fi broblasts and ameliorates angiotensin II-induced myocardial fibrosis in vivo.
DescripciónResumen del póster presentado al XL Congreso de la Sociedad Española de Bioquímica y Biología Molecular (SEBBM), celebrado en Barcelona del 23 al 26 de octubre de 2017.
URIhttp://hdl.handle.net/10261/164872
Aparece en las colecciones: (IBBTEC) Comunicaciones congresos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.